- Home
- CFR vs ROIV Comparison
CFR vs ROIV Comparison
Compare CFR & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CFR | ROIV |
|---|---|---|
| Founded | 1868 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CFR | ROIV |
|---|---|---|
| Price | $128.12 | $21.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $137.50 | $24.31 |
| AVG Volume (30 Days) | 427.3K | ★ 8.4M |
| Earning Date | 01-29-2026 | 02-09-2026 |
| Dividend Yield | ★ 3.11% | N/A |
| EPS Growth | ★ 20.47 | N/A |
| EPS | ★ 9.72 | N/A |
| Revenue | ★ $2,141,575,000.00 | $20,329,000.00 |
| Revenue This Year | $14.17 | N/A |
| Revenue Next Year | $4.47 | $741.42 |
| P/E Ratio | $13.25 | ★ N/A |
| Revenue Growth | ★ 9.02 | N/A |
| 52 Week Low | $100.31 | $8.73 |
| 52 Week High | $146.44 | $23.47 |
Technical Indicators
Market Signals| Indicator | CFR | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 53.55 | 51.17 |
| Support Level | $127.52 | $21.60 |
| Resistance Level | $129.17 | $22.72 |
| Average True Range (ATR) | 2.19 | 0.81 |
| MACD | -0.15 | -0.12 |
| Stochastic Oscillator | 26.97 | 40.78 |
Price Performance
Historical ComparisonAbout CFR Cullen/Frost Bankers Inc.
Cullen/Frost is a regional US bank with around $53 billion in assets (as of September 2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.